One of three Chinese nationals charged with taking bribes from China's United Imaging Healthcare four years ago has copped a plea with federal prosecutors. Yudong Zhu, a Chinese citizen working at New York University, pleaded guilty to lying in a filing for a U.S. National Institutes of Health grant.
Underwriters Laboratories will train 60 food-and-drug inspectors for India's Gujarat state government so that they begin to assess drug manufacturing plants in the same way that U.S. FDA inspectors do.
Glenmark's marketing of a couple of diabetes generics in the United States continues to fluctuate like a yo-yo on a string. Now the India drugmaker can return the drugs to market until April 28.
Sanofi Pasteur counts pediatric vaccines among its 5 key areas, and it's bolstering its offerings in the field with Wednesday's FDA approval of the Quadracel vaccine.
Sun Pharma will start on the hard work now that it has closed on its $4 billion merger of Ranbaxy Laboratories. Managing Director Dilip Shanghvi has pledged that it will get all four of Ranbaxy's sideline plants into 100% compliance with FDA requirements.
After issuing an import alert last year for an IPCA Laboratories API plant in India where employees had been falsifying drug testing results and deleting failed tests, the FDA began looking at its operations further upstream and has now banned products from two of IPCA's finished product facilities.
Swiss-based Actelion Pharmaceuticals was granted marketing approval by Japan's Ministry of Health, Labour and Welfare for Opsumit (macitentan) for the treatment of pulmonary arterial hypertension (PAH).
Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Gilead's Sovaldi (sofosbuvir) for the suppression of viremia in chronic hepatitis C virus, marking the first all-oral, interferon-free treatment regimen for genotype 2 HCV infection and the first product to be marketed by Gilead in Japan.
Indian companies can supply active pharmaceutical ingredients to local research and development companies and institutes, the country's Central Drugs Standard Control Organization said.
Edwards Lifesciences CEO Michael Mussallem testified before Congress on March 24 at a hearing entitled "Continuing America's Leadership: Advancing Research and Development for Patients." His comments focused on improving the FDA's medical device regulatory process, strengthening R&D infrastructure and continued encouragement of innovation.